Bibliografia

Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nat Rev Cancer. 2017 Jan 20.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Lung

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. 

Nat Med. 2018 Jul;24(7):961-967.
Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
Clin Cancer Res. 2017 Jun 15;23(12):3203-3213.
Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Ann Oncol. 2017 Oct 1;28(10):2451-2457.
Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A.

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Nat Med. 2016 Feb 8.
Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z,Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M.

PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion
Cancer Res. 2015 Apr 1;75(7):1287-97.
Bonastre E, Verdura S, Zondervan I, Facchinetti F, Lantuejoul S, Chiara MD, Rodrigo JP, Carretero J, Condom E, Vidal A, Sidransky D, Villanueva A, Roz L, Brambilla E, Savola S, Sanchez-Cespedes M.

Modelling lung cancer evolution and pre-clinical responseallografts by orthotopic mouse
Cancer Res. 2014 Nov 1;74(21):5978-88.
Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sanchez-Cespedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaria D, Villanueva A.

The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer
EMBO Mol Med. 2012 Jul;4(7):603-16.
Romero OA, Setien F, John S, Gimenez-Xavier P, Gómez-López G, Pisano D, Condom E, Villanueva A, Hager GL, Sanchez-Cespedes M.

Ovary

A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination.
Mol Cancer Ther. 2018 Feb;17(2):532-543.
Figueras A, Alsina-Sanchís E, Lahiguera Á, Abreu M, Muinelo-Romay L, Moreno-Bueno G, Casanovas O, Graupera M, Matias-Guiu X, Vidal A, Villanueva A, Viñals F.

TGFβ Controls Ovarian Cancer Cell Proliferation.
Int J Mol Sci. 2017 Jul 30;18(8).
Alsina-Sanchís E, Figueras A, Lahiguera A, Gil-Martín M, Pardo B, Piulats JM, Martí L, Ponce J, Matias-Guiu X, Vidal A, Villanueva A, Viñals F.

Single-cell transcriptome conservation in cryopreserved cells and tissues.
Genome Biol. 2017 Mar 1;18(1):45.
Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H.

The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels
Int J Cancer. 2016 Oct 15;139(8):1894-903.
Alsina-Sanchis E, Figueras A, Lahiguera Á, Vidal A, Casanovas O, Graupera M, Villanueva A, Viñals F.

Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis
Cancer Cell. 2014 Nov 10;26(5):707-21.
Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R.

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
Epigenetics. 2012 Nov;7(11):1225-9.
Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.

Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft ofcisplatin-resistant epithelial ovarian cancer
Clinical Cancer Research. 2012 Oct 1;18(19):5399-411.
Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, Figueras A, Padullés L, García-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Martí L, Ponce J, Molleví DG, Capella G, Condom E, Viñals F, Huertas D, Cuevas C, Esteller M, Avilés P, Villanueva A.

Colon

The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration.  
Sci Rep. 2018 Aug 7;8(1):11797.
Sánchez-Botet A, Gasa L, Quandt E, Hernández-Ortega S, Jiménez J, Mezquita P, Carrasco-García MÀ, Kron SJ, Vidal A, Villanueva A, Ribeiro MPC, Clotet J.

BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent
Sci Signal. 2015 Apr 21;8(373):ra38.
Margalef P, Colomer C, Villanueva A, Montagut C, Iglesias M, Bellosillo B, Salazar R, Martínez-Iniesta M, Bigas A, Espinosa L.

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
Nat Commun. 2014 Apr 3;5:3608.
Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A, Leal L, Wahi JE, Setien-Baranda F, Szczesna K, Moutinho C, Martinez-Cardus A, Heyn H, Sandoval J, Puertas S, Vidal A, Sanjuan X, Martinez-Balibrea E, Viñals F, Perales JC, Bramsem JB, Ørntoft TF, Andersen CL, Tabernero J, McDermott U, Boxer MB, Vander Heiden MG, Albar JP, Esteller M.

A truncated form of IKKα is responsible for specific nuclear IKK activity in colorectal cancer
Cell Rep. 2012 Oct 25;2(4):840-54.
Margalef P, Fernández-Majada V, Villanueva A, Garcia-Carbonell R, Iglesias M, López L, Martínez-Iniesta M, Villà-Freixa J, Mulero MC, Andreu M, Torres F, Mayo MW, Bigas A, Espinosa L.

Intronic RNAs mediate EZH2 regulation of epigenetic targets
Nat Struct Mol Biol. 2012 Jun 3;19(7):664-70.
Guil S, Soler M, Portela A, Carrère J, Fonalleras E, Gómez A, Villanueva A, Esteller M.

Epigenetic disruption of cadherin-11 in human cancer metastasis
J Pathol. 2012 Oct;228(2):230-40.
Carmona FJ, Villanueva A, Vidal A, Muñoz C, Puertas S, Penin RM, Gomà M, Lujambio A, Piulats JM, Mesía R, Sánchez-Céspedes M, Manós M, Condom E, Eccles SA, Esteller M.

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing.
PNAS. 2011 March 15, vol. 108 no. 11 4394-4399.
Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, Esteller M.

A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells
Cancer Cell. 2010 Oct 19;18(4):303-15.
Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, Fernandez AF, Davalos V, Villanueva A, Montoya G, Yamamoto H, Schwartz S Jr, Esteller M.

A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function
Nat Genet. 2009 Mar;41(3):365-70.
Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, Rossi S, Fernandez AF, Carneiro F, Oliveira C, Ferreira B, Liu CG, Villanueva A, Capella G, Schwartz S Jr, Shiekhattar R, Esteller M.

A microRNA DNA methylation signature for human cancer metastasis
PNAS. 2008 Sep 9;105(36):13556-61.
Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M.

Sarcoma

Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine
EMBO Mol Med. 2015 Mar 25. pii: e201404430.
Castellsagué J, Gel B, Fernández-Rodríguez J, Llatjós R, Blanco I, Benavente Y, Pérez-Sidelnikova D, García-Del Muro J, Viñals JM, Vidal A, Valdés-Mas R, Terribas E, López-Doriga A, Pujana MA, Capellá G, Puente XS, Serra E, Villanueva A, Lázaro C.

Breast

Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
Dis Model Mech. 2018 May 18;11(5).
Ruiz de Garibay G, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA.

Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis
Cancer Cell. 2014 Nov 10;26(5):707-21.
Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R.

VAV3 mediates resistance to breast cancer endocrine therapy
Breast Cancer Res. 2014 May 28;16(3):R53.
Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31
Mol Cell. 2014 Mar 6;53(5):806-18
Viré E, Curtis C, Davalos V, Git A, Robson S, Villanueva A, Vidal A, Barbieri I, Aparicio S, Esteller M, Caldas C, Kouzarides T.

Testicular

Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. 
Clin Cancer Res. 2018 Aug 1;24(15):3755-3766.
Piulats JM, Vidal A, García-Rodríguez FJ, Muñoz C, Nadal M, Moutinho C, Martínez-Iniesta M, Mora J, Figueras A, Guinó E, Padullés L, Aytés À, Molleví DG, Puertas S, Martínez-Fernández C, Castillo W, Juliachs M, Moreno V, Muñoz P, Stefanovic M, Pujana MA, Condom E, Esteller M, Germà JR, Capella G, Farré L, Morales A, Viñals F, García-Del-Muro X, Cerón J, Villanueva A.

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors
BMC Cancer. 2013 Aug 10;13:382
Juliachs M, Vidal A, Del Muro XG, Piulats JM, Condom E, Casanovas O, Graupera M, Germà JR, Villanueva A, Viñals F.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors
Clin Cancer Res. 2009 May 15;15(10):3384-95.
Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Glioblastoma

Radioresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program.
Oncotarget. 2017 Jun 3;8(43):73640-73653.
Stanzani E, Martínez-Soler F, Mateos TM, Vidal N, Villanueva A, Pujana MA, Serra-Musach J, de la Iglesia N, Giménez-Bonafé P, Tortosa A.

Endometrium

Patient-Derived Xenograft Models for Endometrial Cancer Research. 
Int J Mol Sci. 2018 Aug 17;19(8).
Moiola CP, Lopez-Gil C, Cabrera S, Garcia A, Van Nyen T, Annibali D, Fonnes T, Vidal A, Villanueva A, Matias-Guiu X, Krakstad C, Amant F, Gil-Moreno A, Colas E.

Melanoma

Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. 
Cancer Metastasis Rev. 2018 Sep;37(2-3):335-345.
Slater K, Hoo PS, Buckley AM, Piulats JM, Villanueva A, Portela A, Kennedy BN.